CME Information

Presented by Columbia University College of Physicians and Surgeons. It is supported by an educational grant from Pfizer Inc.

Target Audience:

This educational activity will target psychiatrists, primary care physicians and other healthcare practitioners who see a significant number of patients with mental illness. The webinar format is chosen because it provides a convenient and cost-effective method of obtaining current information.

Educational Objectives:

The series will address the following Learning Objectives:

• Explain the importance of a fully integrated management team in optimizing patient outcomes and the barriers to communication among healthcare professionals.
• Determine the optimal pharmaceutical regiment for the management of schizophrenia.
• Discuss the importance of treatment adherence in managing schizophrenia.
• Evaluate the efficacy and safety profiles of current and emerging therapies for the treatment of schizophrenia and assess how clinicians can apply this information to improve adherence rates.

Agenda:

• How to Treat Cognitive Dysfunction in Schizophrenia Spectrum Disorders, Alice Medalia, PhD
• The Psychosis Risk Syndrome: Who is Really at Risk? What Can We Do to Prevent Psychosis?, Cheryl Corcoran, MD
• Panel Discussion: Moderator: Philip R. Muskin, MD Participants : Alice Medalia, PhD, Cheryl Corcoran, MD

Faculty:

Course Director, Philip R. Muskin, MD

Cheryl Corcoran, MD

Alice Medalia, PhD

Acknowledgements:

This activity is supported by an educational grant from Pfizer, Inc.

Disclosure of Financial Interest:

As an accredited sponsor, the College of Physicians & Surgeons must ensure balance, independence, objectivity, and scientific rigor in its educational activities. All faculty participating in this activity are required to disclose to the audience any significant financial interest and/or relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in his/her presentation and/or the commercial contributor(s) of this activity.

Detailed Faculty Disclosures:

Dr. Philip R. Muskin

Professor of Clinical Psychiatry, Columbia University College of Physicians & Surgeons, New York

Disclosure—Speakers bureau: AstraZeneca, Bristol-Myers Squibb Company, Otsuka America Pharmaceutical, Inc.

Dr. Muskin has indicated that he will not include reference to off-label/unapproved uses of drugs or devices in his presentation.

Dr. Cheryl Corcoran

Disclosure—Nothing to disclose.

Dr. Corcoran has indicated that she will include reference to off-label/unapproved uses of drugs or devices in her presentation. These will be indicated in the text.

Dr. Alice Medalia

Disclosure—Research Grant: Eli Lilly & Co.

Dr. Medalia has indicated that she will not include reference to off-label/unapproved uses of drugs or devices in her presentation.

Registration Information:

Registration is open to the public and is required in order to complete the CME course and to receive the appropriate credit. Participants are required to choose a password and provide name, contact information, and job role. Job role is required to ensure the correct certificate type is delivered upon course completion.

Intended Audience:

This course is intended for healthcare professionals, including - psychiatrists, primary care physicians and other healthcare practitioners interested in the management of patients with severe mental illness.

Accreditation Statement:

The College of Physicians and Surgeons of Columbia University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement:

The College of Physicians and Surgeons designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™ (3 credits for the online program and 0.5 credits for each of the outcome measurement evaluations).

Credit is available until July 4, 2012.